The spatial folding of chromosomes inside the nucleus has regulatory effects on gene expression, yet the impact of genome reshuffling on this organization remains unclear. Here, we take advantage of chromosome conformation capture in combination with single-nucleotide polymorphism (SNP) genotyping and analysis of crossover events to study how the higher-order chromatin organization and recombination landscapes are affected by chromosomal fusions in the mammalian germ line.
We demonstrate that chromosomal fusions alter the nuclear architecture during meiosis, including an increased rate of heterologous interactions in primary spermatocytes, and alterations in both chromosome synapsis and axis length.
These disturbances in topology were associated with changes in genomic landscapes of recombination, resulting in detectable genomic footprints. Overall, we show that chromosomal fusions impact the dynamic genome topology of germ cells in two ways: (i) altering chromosomal nuclear occupancy and synapsis, and (ii) reshaping landscapes of recombination.
Profiles of immune cell infiltration and immune-related genes in the tumor microenvironment of HNSCC with or without HPV infection
Head and neck squamous cell carcinoma (HNSCC) are the sixth most common cancer type in the world. Human papillomavirus (HPV) infection is an emerging risk factor for HNSCC. Immune infiltration of HNSCC is linked to therapeutic results. This article aimed to decide whether variations in HPV status affect immune infiltration, molecular mechanism, and how these results vary in HNSCC patients.
We investigated the tumor-infiltrating immune cells (TIICs) and immune-related gene differences between HPV (+) and HPV (-) HNSCC. The gene expression quantification data of HNSCC and their clinical information were download from the TCGA database. Immune-related genes have been linked to the ImmPort platform.
After analyzed of 22 TIICs in the HNSCC tumor environment by CIBERSORT and further assessment, lower memory B cell and higher T cell regulatory were connected with better HPV (-) HNSCC outcome, higher activated memory CD4 T cell, higher T cell regulatory, and lower activated NK cell were linked with better HPV (+) result.
We finally got five forms of immune genes (CAMP, EDNRB, NTS, CXCL9, LHB) associated with HNSCC progression. Higher expressions of CAMP, EDNRB, and NTS were associated with increased overall survival in HPV (-) patients. Higher expression of CXCL9 and lower expression of LHB contributed to increased overall survival of HPV (+) patients.
There tend to be discrepancies in the cell structure of TIICs and immune-related genes in HPV (-) and HPV (+) HNSCC. These variances are typically too crucial for the therapeutic outcome of the patient and the development of the tumor. In specific, our sample established these candidate immune cells and immune-related genes as candidate reservoirs for further researches.
Multi-ancestry genome-wide association study identifies 27 loci associated with measures of hemolysis following blood storage
The evolutionary pressure of endemic malaria and other erythrocytic pathogens has shaped variation in genes encoding erythrocyte structural and functional proteins, influencing responses to hemolytic stress during transfusion and disease.
We sought to identify such genetic variants in blood donors by conducting a genome-wide association study (GWAS) of 12,353 volunteer donors, including 1,483 African Americans, 1,477 Asians, and 960 Hispanics, whose stored erythrocytes were characterized by quantitative assays of in vitro osmotic, oxidative, and cold-storage hemolysis.
GWAS revealed 27 significant loci (p<5×10-8), many in candidate genes known to modulate erythrocyte structure, metabolism, and ion channels, including SPTA1, ALDH2, ANK1, HK1, MAPKAPK5, AQP1, PIEZO1, and SLC4A1/Band 3. GWAS of oxidative hemolysis identified variants in antioxidant enzymes including GLRX, GPX4, G6PD, and a novel golgi-transport protein SEC14L4.
Genome wide significant loci were also tested for association with the severity of steady state (baseline) in vivo hemolytic anemia in patients with sickle cell disease, with confirmation of identified SNPs in HBA2, G6PD, PIEZO1, AQP1 and SEC14L4. Many of the identified variants, such as those in G6PD, have previously been shown to impair erythrocyte recovery after transfusion, associate with anemia, or cause rare Mendelian human hemolytic diseases.
Candidate SNPs in these genes, especially in polygenic combinations, may affect RBC recovery after transfusion and modulate disease severity in hemolytic diseases, such as sickle cell disease and malaria.

stjosephs-hospital
Incorporating Genomic and Genetic Testing into the Treatment of Metastatic Luminal Breast Cancer
Background: Treatment of patients with luminal metastatic breast cancer (MBC) has become even more complex over the last few years as molecular profiling has begun to alter disease management. It is well accepted that MBC is not curable but is treatable. Today we are able to prolong progression-free survival and partly overall survival with targeted and more individual treatment strategies adjusted according to the molecular subtype.
Summary: Genetic and genomic testing has become therapeutically relevant in luminal MBC and is therefore an integral component within the treatment spectrum. By now, germline testing of BRCABRCAPIK3CA mutations are inevitable elements in disease management and the current state of the art in luminal MBC patients.
Furthermore, testing of ESR1 resistance mutation, ERBB2 mutation, microsatellite instability, and neurotrophic tyrosine receptor kinase (NTRK) gene fusion (mainly in secretory breast cancer) has recently gained increasing attention. However, based on the expanding role of personalized medicine, clinicians are now faced with substantial new challenges and possibly unsuspected possibilities. The following review summarizes current developments in genetic and genomic testing in luminal MBC.
Key messages: In luminal MBC genomics have become an integral component within the spectrum of oncological treatment establishing novel therapeutic facilities. Further developments in treatment personalization adjusted according to the molecular subtype should become increasingly important in order to enhance the progress of de-escalation of chemotherapy in luminal MBC. However, based on the expanding role of personalized medicine, clinicians are now faced with substantial new challenges and possibly unsuspected possibilities.
HIV-1 p24 ELISA Kit |
Z7040001 |
Biochain |
1 kit |
EUR 812 |
Description: Premade ready to use kits will always come in handy. Get your experiment done right form the first try by using a validated kit with perfectly balanced reagents proportions and compatibility and by following a clear protocol. |
HIV-1 p24 |
E5-00024 |
EnoGene |
1mg |
EUR 960 |
HIV-1 p24 |
E62H002 |
EnoGene |
100ug |
EUR 382 |
HIV Type 1 p24 Antigen ELISA (96 Determinations) |
0801111 |
Zeptometrix |
96T |
EUR 548.16 |
|
Description: Please contact Gentaur in order to receive the datasheet of the product. |
HIV Type 1 p24 Antigen ELISA 2.0 (96 Determinations) |
0801002 |
Zeptometrix |
96T |
EUR 548.16 |
|
Description: Please contact Gentaur in order to receive the datasheet of the product. |
HIV-1 p24 Antibody |
20-abx137062 |
Abbexa |
|
|
|
HIV 1 p24 Protein |
abx060589-1mg |
Abbexa |
1 mg |
EUR 1288 |
|
HIV-1 p24 Protein |
abx061424-05mg |
Abbexa |
0.5 mg |
EUR 739 |
|
HIV-1, p24 Protein |
abx069857-1mg |
Abbexa |
1 mg |
EUR 1574 |
|
HIV-1 p24 Antibody |
abx021869-1mg |
Abbexa |
1 mg |
EUR 662 |
|
HIV-1 p24 Antibody |
abx021870-1mg |
Abbexa |
1 mg |
EUR 634 |
|
HIV-1 p24 Antibody |
abx021871-1mg |
Abbexa |
1 mg |
EUR 662 |
|
HIV-1 p24 Antibody |
abx021872-1mg |
Abbexa |
1 mg |
EUR 662 |
|
HIV-1 p24 Antibody |
abx021873-1mg |
Abbexa |
1 mg |
EUR 662 |
|
HIV-1 p24 Antibody |
abx021882-1mg |
Abbexa |
1 mg |
EUR 982 |
|
HIV-1 p24 Antibody |
abx021883-1mg |
Abbexa |
1 mg |
EUR 1017 |
|
HIV-1 p24 Antibody |
abx021886-1mg |
Abbexa |
1 mg |
EUR 1017 |
|
HIV-1 p24 Antibody |
abx021887-1mg |
Abbexa |
1 mg |
EUR 1017 |
|
HIV-1 p24 Antibody |
abx021888-1mg |
Abbexa |
1 mg |
EUR 1017 |
|
HIV-1 p24 Antibody |
abx023027-1ml |
Abbexa |
1 ml |
EUR 578 |
|
HIV-1 p24 Antibody |
abx023925-1mg |
Abbexa |
1 mg |
EUR 690 |
|
HIV-1 p24 Antibody |
abx023926-1mg |
Abbexa |
1 mg |
EUR 690 |
|
HIV-1 p24 Protein |
abx169032-1mg |
Abbexa |
1 mg |
EUR 551 |
|
HIV-1 p24 Protein |
20-abx261886 |
Abbexa |
-
EUR 4490.00
-
EUR 328.00
-
EUR 230.00
|
|
|
HIV-1 Gag p24 |
05-005 |
Sceti |
50 ug |
EUR 362 |
Description: The HIV-1 Gag p24 is available in Europe and for worldwide shipping via Gentaur. |
HIV-1 Gag p24 |
05-006 |
Sceti |
250 ug |
EUR 962 |
Description: The HIV-1 Gag p24 is available in Europe and for worldwide shipping via Gentaur. |
HIV-1 p24 Antibody |
7313-002mg |
ProSci |
0.02 mg |
EUR 171.82 |
|
Description: HIV-1 p24 Antibody: The human immunodeficiency virus type 1 (HIV-1) particle consists of an envelope, a core and the region between the two termed matrix. The HIV-1 Gag protein is a late structural protein that contains four proteins: matrix (p17), capsid (p24), nucleocapsid (p7) and the p6 protein. The p24 is the major capsid protein of the virus and has been used in clinical trials as one of the components of the HIV-1 vaccine because of the high degree of sequence conservation between different strains. |
HIV-1 p24 Antibody |
7313-01mg |
ProSci |
0.1 mg |
EUR 436.42 |
|
Description: HIV-1 p24 Antibody: The human immunodeficiency virus type 1 (HIV-1) particle consists of an envelope, a core and the region between the two termed matrix. The HIV-1 Gag protein is a late structural protein that contains four proteins: matrix (p17), capsid (p24), nucleocapsid (p7) and the p6 protein. The p24 is the major capsid protein of the virus and has been used in clinical trials as one of the components of the HIV-1 vaccine because of the high degree of sequence conservation between different strains. |
p24-HIV(p24/661) Antibody |
BNCA0661-250 |
Biotium |
250uL |
EUR 383 |
Description: Primary antibody against p24-HIV(p24/661), APC conjugate, Concentration: 0.1mg/mL |
p24-HIV(p24/661) Antibody |
BNCAP0661-100 |
Biotium |
100uL |
EUR 199 |
Description: Primary antibody against p24-HIV(p24/661), Alkaline Phosphatase conjugate, Concentration: 0.1mg/mL |
p24-HIV(p24/661) Antibody |
BNCAP0661-500 |
Biotium |
500uL |
EUR 544 |
Description: Primary antibody against p24-HIV(p24/661), Alkaline Phosphatase conjugate, Concentration: 0.1mg/mL |
p24-HIV(p24/661) Antibody |
BNC810661-100 |
Biotium |
100uL |
EUR 199 |
Description: Primary antibody against p24-HIV(p24/661), CF680R conjugate, Concentration: 0.1mg/mL |
p24-HIV(p24/661) Antibody |
BNC810661-500 |
Biotium |
500uL |
EUR 544 |
Description: Primary antibody against p24-HIV(p24/661), CF680R conjugate, Concentration: 0.1mg/mL |
p24-HIV(p24/661) Antibody |
BNC880661-100 |
Biotium |
100uL |
EUR 199 |
Description: Primary antibody against p24-HIV(p24/661), CF488A conjugate, Concentration: 0.1mg/mL |
p24-HIV(p24/661) Antibody |
BNC880661-500 |
Biotium |
500uL |
EUR 544 |
Description: Primary antibody against p24-HIV(p24/661), CF488A conjugate, Concentration: 0.1mg/mL |
p24-HIV(p24/661) Antibody |
BNCB0661-100 |
Biotium |
100uL |
EUR 199 |
Description: Primary antibody against p24-HIV(p24/661), Biotin conjugate, Concentration: 0.1mg/mL |
p24-HIV(p24/661) Antibody |
BNCB0661-500 |
Biotium |
500uL |
EUR 544 |
Description: Primary antibody against p24-HIV(p24/661), Biotin conjugate, Concentration: 0.1mg/mL |
p24-HIV(p24/661) Antibody |
BNC550661-100 |
Biotium |
100uL |
EUR 199 |
Description: Primary antibody against p24-HIV(p24/661), CF555 conjugate, Concentration: 0.1mg/mL |
p24-HIV(p24/661) Antibody |
BNC550661-500 |
Biotium |
500uL |
EUR 544 |
Description: Primary antibody against p24-HIV(p24/661), CF555 conjugate, Concentration: 0.1mg/mL |
p24-HIV(p24/661) Antibody |
BNC430661-100 |
Biotium |
100uL |
EUR 199 |
Description: Primary antibody against p24-HIV(p24/661), CF543 conjugate, Concentration: 0.1mg/mL |
p24-HIV(p24/661) Antibody |
BNC430661-500 |
Biotium |
500uL |
EUR 544 |
Description: Primary antibody against p24-HIV(p24/661), CF543 conjugate, Concentration: 0.1mg/mL |
p24-HIV(p24/661) Antibody |
BNC470661-100 |
Biotium |
100uL |
EUR 199 |
Description: Primary antibody against p24-HIV(p24/661), CF647 conjugate, Concentration: 0.1mg/mL |
p24-HIV(p24/661) Antibody |
BNC470661-500 |
Biotium |
500uL |
EUR 544 |
Description: Primary antibody against p24-HIV(p24/661), CF647 conjugate, Concentration: 0.1mg/mL |
p24-HIV(p24/661) Antibody |
BNC940661-100 |
Biotium |
100uL |
EUR 199 |
Description: Primary antibody against p24-HIV(p24/661), CF594 conjugate, Concentration: 0.1mg/mL |
p24-HIV(p24/661) Antibody |
BNC940661-500 |
Biotium |
500uL |
EUR 544 |
Description: Primary antibody against p24-HIV(p24/661), CF594 conjugate, Concentration: 0.1mg/mL |
p24-HIV(p24/661) Antibody |
BNCP0661-250 |
Biotium |
250uL |
EUR 383 |
Description: Primary antibody against p24-HIV(p24/661), PerCP conjugate, Concentration: 0.1mg/mL |
p24-HIV(p24/661) Antibody |
BNC040661-100 |
Biotium |
100uL |
EUR 199 |
Description: Primary antibody against p24-HIV(p24/661), CF405S conjugate, Concentration: 0.1mg/mL |
p24-HIV(p24/661) Antibody |
BNC040661-500 |
Biotium |
500uL |
EUR 544 |
Description: Primary antibody against p24-HIV(p24/661), CF405S conjugate, Concentration: 0.1mg/mL |
p24-HIV(p24/661) Antibody |
BNC050661-100 |
Biotium |
100uL |
EUR 199 |
Description: Primary antibody against p24-HIV(p24/661), CF405M conjugate, Concentration: 0.1mg/mL |
p24-HIV(p24/661) Antibody |
BNC050661-500 |
Biotium |
500uL |
EUR 544 |
Description: Primary antibody against p24-HIV(p24/661), CF405M conjugate, Concentration: 0.1mg/mL |
p24-HIV(p24/661) Antibody |
BNCR0661-250 |
Biotium |
250uL |
EUR 383 |
Description: Primary antibody against p24-HIV(p24/661), RPE conjugate, Concentration: 0.1mg/mL |
p24-HIV(p24/661) Antibody |
BNUB0661-100 |
Biotium |
100uL |
EUR 209 |
Description: Primary antibody against p24-HIV(p24/661), Concentration: 0.2mg/mL |
p24-HIV(p24/661) Antibody |
BNUB0661-500 |
Biotium |
500uL |
EUR 458 |
Description: Primary antibody against p24-HIV(p24/661), Concentration: 0.2mg/mL |
p24-HIV(p24/661) Antibody |
BNC680661-100 |
Biotium |
100uL |
EUR 199 |
Description: Primary antibody against p24-HIV(p24/661), CF568 conjugate, Concentration: 0.1mg/mL |
p24-HIV(p24/661) Antibody |
BNC680661-500 |
Biotium |
500uL |
EUR 544 |
Description: Primary antibody against p24-HIV(p24/661), CF568 conjugate, Concentration: 0.1mg/mL |
p24-HIV(p24/661) Antibody |
BNC700661-100 |
Biotium |
100uL |
EUR 199 |
Description: Primary antibody against p24-HIV(p24/661), CF770 conjugate, Concentration: 0.1mg/mL |
p24-HIV(p24/661) Antibody |
BNC700661-500 |
Biotium |
500uL |
EUR 544 |
Description: Primary antibody against p24-HIV(p24/661), CF770 conjugate, Concentration: 0.1mg/mL |
p24-HIV(p24/661) Antibody |
BNC400661-100 |
Biotium |
100uL |
EUR 199 |
Description: Primary antibody against p24-HIV(p24/661), CF640R conjugate, Concentration: 0.1mg/mL |
p24-HIV(p24/661) Antibody |
BNC400661-500 |
Biotium |
500uL |
EUR 544 |
Description: Primary antibody against p24-HIV(p24/661), CF640R conjugate, Concentration: 0.1mg/mL |
p24-HIV(p24/661) Antibody |
BNC610661-100 |
Biotium |
100uL |
EUR 199 |
Description: Primary antibody against p24-HIV(p24/661), CF660R conjugate, Concentration: 0.1mg/mL |
p24-HIV(p24/661) Antibody |
BNC610661-500 |
Biotium |
500uL |
EUR 544 |
Description: Primary antibody against p24-HIV(p24/661), CF660R conjugate, Concentration: 0.1mg/mL |
p24-HIV(p24/661) Antibody |
BNC800661-100 |
Biotium |
100uL |
EUR 199 |
Description: Primary antibody against p24-HIV(p24/661), CF680 conjugate, Concentration: 0.1mg/mL |
p24-HIV(p24/661) Antibody |
BNC800661-500 |
Biotium |
500uL |
EUR 544 |
Description: Primary antibody against p24-HIV(p24/661), CF680 conjugate, Concentration: 0.1mg/mL |
p24-HIV(p24/661) Antibody |
BNCH0661-100 |
Biotium |
100uL |
EUR 199 |
Description: Primary antibody against p24-HIV(p24/661), Horseradish Peroxidase conjugate, Concentration: 0.1mg/mL |
p24-HIV(p24/661) Antibody |
BNCH0661-500 |
Biotium |
500uL |
EUR 544 |
Description: Primary antibody against p24-HIV(p24/661), Horseradish Peroxidase conjugate, Concentration: 0.1mg/mL |
p24-HIV(p24/661) Antibody |
BNUM0661-50 |
Biotium |
50uL |
EUR 395 |
Description: Primary antibody against p24-HIV(p24/661), 1mg/mL |
HIV p24 Antibody |
abx021867-1mg |
Abbexa |
1 mg |
EUR 1344 |
|
HIV p24 Antibody |
abx021868-1mg |
Abbexa |
1 mg |
EUR 1344 |
|
HIV Type 1 p24 Antigen ELISA (5 X 96 Determinations) |
0801200 |
Zeptometrix |
5 X 96T |
EUR 2119.6 |
|
Description: Please contact Gentaur in order to receive the datasheet of the product. |
HIV-1 p24, His tag |
E410A26-20 |
EnoGene |
20μg |
EUR 434 |
Recombinant HIV-1 p24 Core |
7-07599 |
CHI Scientific |
1000µg |
Ask for price |
Recombinant HIV-1 p24 , 24kDa |
7-07621 |
CHI Scientific |
2µg |
Ask for price |
Recombinant HIV-1 p24 , 24kDa |
7-07622 |
CHI Scientific |
10µg |
Ask for price |
Recombinant HIV-1 p24 , 24kDa |
7-07623 |
CHI Scientific |
100µg |
Ask for price |
HIV 1 / 2 p24 Antibody |
abx021866-1mg |
Abbexa |
1 mg |
EUR 1010 |
|
HIV-1 p24 Antibody (FITC) |
abx021884-100ug |
Abbexa |
100 ug |
EUR 739 |
|